Drug intelligence / Profile preview

Akeli capsule

Development stage: Unknown
Lead developer: Jiren Pharmaceutical
Administration: Oral

Overview

Akeli capsule is an orally administered proprietary traditional Chinese medicine capsule developed by Shaanxi Ankang Jiren Pharmaceutical for **type 2 diabetes mellitus with Qi and Yin deficiency syndrome**. A completed randomized, double-blind, double-dummy, parallel-group Phase 2 trial evaluated the product against glipizide, with objectives including assessment of glycemic control and improvement of Qi and Yin deficiency symptoms. Publicly available sources do not disclose the capsule's ingredient composition, molecular targets, or a validated pharmacologic mechanism.

Other names: Ake capsule阿克胶囊阿克里胶囊

Beyond the preview

Go deeper on Akeli capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akeli capsule.

Explore the full profile